Treatment Strategy for Vasculitis with Anti-Histone Antibodies
Anti-histone antibodies in the context of vasculitis typically indicate drug-induced ANCA-associated vasculitis (most commonly from hydralazine), and the primary treatment is immediate discontinuation of the offending drug combined with standard ANCA vasculitis induction therapy using glucocorticoids plus either rituximab or cyclophosphamide, depending on disease severity.
Critical First Step: Identify and Stop the Culprit Drug
Anti-histone antibodies are a hallmark of drug-induced vasculitis, particularly from:
- Hydralazine (most common cause) 1, 2
- Ibuprofen and other NSAIDs 3
- Other medications associated with drug-induced lupus
Immediately discontinue the suspected medication - this is essential as continued exposure perpetuates the disease process 3, 1.
Induction Therapy Based on Disease Severity
For Organ-Threatening or Life-Threatening Disease
Use glucocorticoids combined with either rituximab or cyclophosphamide 4, 5:
Glucocorticoid dosing 5:
- Start with 50-75 mg prednisolone equivalent daily (weight-based: <50kg = 50mg, 50-75kg = 60mg, >75kg = 75mg)
- Taper according to structured protocol reaching 5mg daily by 4-5 months
- Continue low-dose (5-7.5mg daily) for 2 years, then reduce by 1mg every 2 months
Immunosuppression options 5:
Rituximab:
- 375 mg/m² weekly × 4 weeks, OR
- 1000mg on days 1 and 15
Cyclophosphamide (if rituximab unavailable):
- IV: 15 mg/kg at weeks 0,2,4,7,10,13
- Oral: 2 mg/kg/day for 3 months (reduce for age >60 years and renal impairment)
For severe presentations (creatinine >300 µmol/L or diffuse alveolar hemorrhage with hypoxemia), consider adding plasma exchange 5.
For Non-Organ-Threatening Disease
Use glucocorticoids plus rituximab as first-line 4. Methotrexate or mycophenolate mofetil can be considered as alternatives to rituximab 4.
Drug-Induced Vasculitis Specific Considerations
The evidence from drug-induced cases 1, 2 demonstrates that:
- Hydralazine-induced ANCA vasculitis can be severe, causing crescentic glomerulonephritis requiring dialysis
- Treatment follows standard ANCA vasculitis protocols (steroids + rituximab or cyclophosphamide ± plasmapheresis)
- Drug discontinuation alone may be insufficient for severe disease - immunosuppression is still required 1, 2
- Some cases show complete remission after drug withdrawal and treatment 3, but severe cases may result in chronic kidney disease or death 1
Maintenance Therapy
After achieving remission, maintenance therapy is essential 5:
Preferred: Rituximab 5:
- 500mg × 2 at remission, then 500mg at months 6,12,18 (MAINRITSAN protocol), OR
- 1000mg at months 4,8,12,16 after induction (RITAZAREM protocol)
Alternative: Azathioprine 5:
- 1.5-2 mg/kg/day at complete remission
- Continue for 1 year, then decrease by 25mg every 3 months
- Can extend to 4 years in high-risk patients
Duration: 18 months to 4 years after induction of remission 5.
Key Clinical Pitfalls
Don't assume drug withdrawal alone is sufficient - severe drug-induced ANCA vasculitis requires full immunosuppressive therapy 1, 2
Anti-histone antibodies don't change the treatment algorithm - they help identify drug-induced etiology but treatment follows standard ANCA vasculitis protocols 4, 5
Monitor for relapse even after drug discontinuation - maintenance therapy is still required 5
Consider rituximab over cyclophosphamide in drug-induced cases given the favorable safety profile and equivalent efficacy 4, 2
Assess for renal and pulmonary involvement urgently - hydralazine-induced vasculitis commonly presents as pulmonary-renal syndrome requiring aggressive therapy 1, 2